Macrogenics Inc (NAS:MGNX)
$ 4.36 0.25 (6.07%) Market Cap: 273.08 Mil Enterprise Value: 107.83 Mil PE Ratio: 0 PB Ratio: 2.57 GF Score: 62/100

MacroGenics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 09, 2021 / 01:00PM GMT
Release Date Price: $21.27 (+2.11%)
John Hoffman

Good morning everybody, Thank you so much for joining the Credit Suisse 30th Annual Healthcare Conference. This is John Hoffman from ECM team speaking, pleasure to have you all here today. I'm joined this morning by Scott Koenig, CEO of MacroGenics regarding the corporate update. Scott, I'd like to turn the floor over to you.

Scott Koenig
MacroGenics, Inc. - CEO, President & Director

Thank you very much, John. Thank you for the opportunity to present at the Credit Suisse conference. I'll be making forward-looking statements during my presentation so please refer to our SEC filings to understand the risks investing in MacroGenics. 2021 was the year of significant advancement for MacroGenics, we launched MARGENZA our first in-house develop proprietory product with our partner EVERSANA in March. We advanced our B7-H3 portfolio and continue to demonstrate the value of our technology platforms which include our bispecific DART technology, our Fc Optimization platform and our ADC-based antibody molecules. Out of 9 molecules in clinical development we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot